Randomized clinical trials have limitations because they focus on small samples of highly selected patients. Observational studies, which follow large cohorts of typical patients receiving pharmacological treatments, should overcome some of these trial limitations and provide information that cannot be generated with clinical trials. The present study aimed to compare experimental and observational studies of clozapine-treated subjects with treatment-resistant schizophrenia. A systematic review of experimental and observational studies evaluating clozapine-treated subjects in treatment-resistant schizophrenia was carried out. We identified 50 studies that met the inclusion criteria. Less than one-third of clinical trials enrolled more than ...
Background: Several lines of evidence suggest that clozapine is more effective than both first- and ...
BackgroundFor around a third of people with a diagnosis of schizophrenia, the condition proves to re...
Reducing the risk of violent and aggressive behaviour in patients with schizophrenia remains a clini...
Randomized clinical trials have limitations because they focus on small samples of highly selected p...
Clozapine is seldom prescribed in treatment-resistant schizophrenia (TRS) patients during early phas...
Background Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to c...
BACKGROUND: The aim of this study was to evaluate the long-term efficacy and safety of clozapine ...
Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associate...
There is good evidence that clozapine is more efficacious than first-generation antipsychotic drugs ...
For years, the management of schizophrenia has represented a challenge for clinicians, with antipsyc...
For years, the management of schizophrenia has represented a challenge for clinicians, with antipsyc...
Clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who ar...
Treatment resistance causes significant burden in psychosis. Clozapine is the only evidence-based ph...
Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatme...
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. ...
Background: Several lines of evidence suggest that clozapine is more effective than both first- and ...
BackgroundFor around a third of people with a diagnosis of schizophrenia, the condition proves to re...
Reducing the risk of violent and aggressive behaviour in patients with schizophrenia remains a clini...
Randomized clinical trials have limitations because they focus on small samples of highly selected p...
Clozapine is seldom prescribed in treatment-resistant schizophrenia (TRS) patients during early phas...
Background Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to c...
BACKGROUND: The aim of this study was to evaluate the long-term efficacy and safety of clozapine ...
Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associate...
There is good evidence that clozapine is more efficacious than first-generation antipsychotic drugs ...
For years, the management of schizophrenia has represented a challenge for clinicians, with antipsyc...
For years, the management of schizophrenia has represented a challenge for clinicians, with antipsyc...
Clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who ar...
Treatment resistance causes significant burden in psychosis. Clozapine is the only evidence-based ph...
Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatme...
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. ...
Background: Several lines of evidence suggest that clozapine is more effective than both first- and ...
BackgroundFor around a third of people with a diagnosis of schizophrenia, the condition proves to re...
Reducing the risk of violent and aggressive behaviour in patients with schizophrenia remains a clini...